Generic placeholder image

Reviews on Recent Clinical Trials


ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Iodine-Refractory Thyroid Carcinoma

Author(s): Apar K. Ganti and Ezra E.W. Cohen

Volume 1, Issue 2, 2006

Page: [133 - 141] Pages: 9

DOI: 10.2174/157488706776876526

Price: $65


The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodinerefractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.

Keywords: thyroid stimulating hormone, RET/PTC oncogene, TP53 Tumor Suppressor Gene, Chemotherapy, vascular endothelial growth factor (VEGF)

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy